SCHEMBL2571304

SCHEMBL2571304

Cc1n[nH]cc1-c1nc(-c2cnn(C)c2)cc2nccn12

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 6/20 0.39
KDM5B Q9UGL1 1/20 0.37
MAPK1 P28482 2/20 0.36
ADORA2A P29274 1/20 0.36
CSF1R P07333 1/20 0.35
FLT3 P36888 1/20 0.35
JAK2 O60674 3/20 0.35
TYK2 P29597 3/20 0.35
MAPT P10636 1/20 0.35
CCNC P24863 2/20 0.35
CDK8 P49336 2/20 0.35
TNK2 Q07912 1/20 0.35
JAK1 P23458 2/20 0.35
CHEK1 O14757 1/20 0.34
CHEK2 O96017 1/20 0.34
LRRK2 Q5S007 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2561514 0.82 CHEK1 (0.48) PIM1KDM5BMAPK1ADORA2AFLT3
Hydrochloric Acid SCHEMBL14863956 0.81 CHEK1 (0.47) PIM1KDM5BMAPK1ADORA2AFLT3
Hydrochloric Acid SCHEMBL2573142 0.80 PIM1 (0.40) PIM1KDM5BMAPK1ADORA2AMAPT
SCHEMBL2574412 0.80 MAPK1 (0.40) PIM1KDM5BMAPK1ADORA2AFLT3
SCHEMBL2574553 0.77 AHR (0.43) MAPK1JAK2MAPTTNK2
SCHEMBL14863891 0.75 TNK2 (0.38) PIM1KDM5BMAPK1ADORA2AFLT3
SCHEMBL24438190 0.74 FYN (0.43) PIM1KDM5BADORA2AFLT3JAK2
SCHEMBL2553734 0.74 FGFR3 (0.45) PIM1KDM5BMAPK1ADORA2AFLT3
SCHEMBL12287668 0.74 TYK2 (0.42) JAK2TYK2JAK1
SCHEMBL14873657 0.74 TNK2 (0.36) PIM1KDM5BADORA2AJAK2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558468-B1 5, 7-SUBSTITUTED-IMIDAZO [1,2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC (US) 2015-04-01 EP disclosed
US-8962596-B2 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases ARRAY BIOPHARMA INC. (US) 2015-02-24 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
EP-2558468-A1 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES Array Biopharma, Inc. (US) 2013-02-20 EP disclosed
WO-2011130146-A1 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES JAK1, JAK3, JAK2 PIM1 211/4885KDM5B 1149/4885MAPK1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.